Dr. Glenn Dranoff is the global head of Immuno-Oncology at the Novartis Institutes for Biomedical Research.
Dr. Dranoff has been instrumental in the development of several immunotherapies, most notably the vaccine G-VAX, which helps stimulate the immune system against tumors using irradiated cancer cells. In recognition of these and other accomplishments, Dr. Dranoff received the 2015 William B. Coley Award for Distinguished Research in Tumor Immunology, the Eli Lilly Biochemistry Award in Gene Therapy, and was inducted into the American Association of Physicians. Now, his work focuses on developing effective combinations of immunotherapies, including vaccines and checkpoint inhibitors, and advancing the most promising strategies into clinical trials to benefit patients.
In addition to his role as an associate director of CRI’s Scientific Advisory Council, Dr. Dranoff is a member of the Cancer Immunotherapy Consortium (CIC) Steering Committee and was the founding editor-in-chief of the CRI/AACR journal Cancer Immunology Research.
The field has matured to a point that we can come up with reasonable hypotheses on how to apply and combine immunotherapies based on clinical data. It’s a remarkable privilege to be working at this time, when the expectations are quite high for making significant advances across a large array of dreadful diseases.
Let's spread the word about Immunotherapy! Click to share this page with your community.